Fall 2026
Account Management Intern
BGBx
501-1,000 employees
Healthcare consultancy translating science into stories
No salary listed
United States
In Person
Fall 2026 internship runs September–December 2026; eligible for academic credit through college/university.
 Sales & Account Management (1) |
|---|
Get referred to BGBx
See people who can refer or advise you
- Will be graduating this spring 2027 or 2028 with a Bachelor’s or Master’s degree in science, communications, marketing/advertising, or healthcare
- Have a strong career interest in healthcare communications/pharma advertising
- Are self-starters that take initiative and think quickly on their feet
- Possess strong verbal, presentation, and written communication skills
- Enjoy interacting with people and have a track record of working successfully in a team-based environment
- Want an exciting internship opportunity for school credit, with potential for future full-time employment
- Researching background information on new products and/or therapy areas
- Brainstorming new ideas for projects or new business initiatives
- Preparing materials for internal and client meetings
- Assistance on active projects in development
- Producing meeting summaries and following up on next steps with team members
- Developing company marketing and communications
- Planning internal agency programs and events
BGBx is a healthcare consultancy that helps pharmaceutical, biotech, and medical device companies turn scientific advances into practical, credible brand stories and strategies. Its services include medical communications to explain science clearly, market access planning to help products reach patients, and payer strategy to work with insurance decision-makers. The work is done by a team that combines clinical knowledge, academic insight, and industry experience, and is delivered through project-based engagements that aim for real-time, real-world impact. Unlike firms that rely on generic marketing, BGBx differentiates itself with a strong, multidisciplinary medical team and a clear focus on translating science into strategies that improve access and outcomes. The company’s goal is to help clients communicate complex science effectively while shaping reimbursement and market access to bring new therapies and devices to patients more efficiently.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
2014
Get referred to BGBx
See people who can refer or advise you
Simplify's Take
What believers are saying
- The June 2026 rebrand supports larger strategic engagements across the commercial lifecycle.
- Payer communications aligns with growing client demand for access and reimbursement support.
- Unified consulting and communications improves cross-functional execution for pharmaceutical and biotech brands.
What critics are saying
- Big pharma in-house teams reduce demand for project-based consulting and agency work.
- A generic commercial-solutions rebrand weakens pricing power if differentiation is unclear.
- Compliance missteps in promotional or payer communications can quickly damage trust and retention.
What makes BGBx unique
- BGBx combines consulting and communications under one independent commercial-solution platform.
- Its teams blend clinical, academic, industry, creative, data, and technology expertise.
- BGBx covers strategy, market access, payer communications, advertising, and medical communications.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 5%BGB Group, a commercial solutions company for biopharmaceutical firms, has acquired Hayden Consulting Group, a market access and patient services consultancy. Financial terms were not disclosed. Hayden specialises in resolving complex payer, reimbursement and affordability challenges for global pharmaceutical brands. The acquisition combines Hayden's market access expertise with BGB's strategic advisory services, which span commercial due diligence, new product planning and go-to-market strategies. Hayden will continue to be led by co-founders Jamie Sidore and David MacDougall, becoming part of BGB's strategic advisory practice headed by Hilary Gentile. The combined entity aims to provide clients with integrated solutions across the full brand lifecycle, from early planning through commercialisation.
BGB Group appoints David Coman as Chief Executive Officer.
BGB Group recently hired Chris Palmer as its new chief creative officer, who joined from Havas Life New York.
Kuzel comes to imre from BGB Group, where she was EVP data, analytics and customer experience.
NEW YORK--(BUSINESS WIRE)--BGB Group (BGB), an award-winning healthcare commercialization and communications company headquartered in New York City with offices in Washington DC, Boston, and London, today announced a strategic partnership with Scrum50 (S50), a dynamic, agile-first creative agency based in South Norwalk, CT. This collaboration marks a transformative alliance, the next phase of BGB’s expertise enhancement aimed at remaining ahead of biopharma’s biggest challenges. The teams are set to redefine creativity and impact in the healthcare sector. S50 will continue to operate independently across all industry sectors. “We are excited to formalize our partnership with S50,” noted Greg Passaretti, Founding Partner of BGB Group. “We’ve been working together for nearly a year, and we realized that there’s much more that we can accomplish for a marketplace in need of broader creative and engagement solutions.”